Great question! Here's a breakdown of when Vyndamax (tafamidis) and Amvuttra (vutrisiran) are used in wild-type ATTR amyloidosis treatment.
Vyndamax (tafamidis)
Vyndamax is an FDA-approved TTR stabilizer. It works by helping the transthyretin protein keep its correct shape, which prevents it from misfolding and building Show Full Answer
Great question! Here's a breakdown of when Vyndamax (tafamidis) and Amvuttra (vutrisiran) are used in wild-type ATTR amyloidosis treatment.
Vyndamax (tafamidis)
Vyndamax is an FDA-approved TTR stabilizer. It works by helping the transthyretin protein keep its correct shape, which prevents it from misfolding and building up as amyloid deposits in the heart. It is approved specifically for cardiomyopathy (heart involvement) caused by wild-type or hereditary ATTR amyloidosis.
Key cautions to be aware of:
- Watch for signs of an allergic reaction, such as trouble swallowing, hives, chest tightness, or a fast heartbeat — seek medical attention immediately if these occur
- It is taken orally (by mouth) Amvuttra (vutrisiran)
Amvuttra works differently — it's a gene silencer that reduces the liver's production of the transthyretin protein, helping to prevent amyloid buildup and organ damage. It was approved in March 2025 to treat ATTR cardiomyopathy (ATTR-CM), which includes wild-type amyloidosis with heart involvement.
Common side effects of Amvuttra include:
- Sore throat
- Joint pain
- Muscle pain and spasms
- Headache
Both medications target heart involvement, so a cardiologist will typically guide treatment decisions. Always discuss with your care team which option best fits your health profile, lifestyle, and insurance coverage.
July 6
Join
Your Privacy Choices
